Narayanaswamy Rohini, Iyer Vignesh, Khare Prachi, Bodziak Mary Lou, Badgett Darlene, Zivadinov Robert, Weinstock-Guttman Bianca, Rideout Todd C, Ramanathan Murali, Browne Richard W
Department of Biotechnical and Clinical Laboratory Sciences, University at Buffalo, State University of New York, Buffalo, New York, United States of America.
Department of Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, New York, United States of America.
PLoS One. 2015 Apr 13;10(4):e0123771. doi: 10.1371/journal.pone.0123771. eCollection 2015.
Oxysterols are promising biomarkers of neurodegenerative diseases that are linked with cholesterol and vitamin D metabolism. There is an unmet need for methods capable of sensitive, and simultaneous quantitation of multiple oxysterols, vitamin D and cholesterol pathway biomarkers.
A method for simultaneous determination of 5 major oxysterols, 25-hydroxy vitamin D3 and cholesterol in human plasma was developed. Total oxysterols were prepared by room temperature saponification followed by solid phase extraction from plasma spiked with deuterated internal standards. Oxysterols were resolved by reverse phase HPLC using a methanol/water/0.1% formic acid gradient. Oxysterols and 25-hydroxy vitamin D3 were detected with atmospheric pressure chemical ionization mass spectrometry in positive ion mode; in-series photodiode array detection at 204nm was used for cholesterol. Method validation studies were performed. Oxysterol levels in 220 plasma samples from healthy control subjects, multiple sclerosis and other neurological disorders patients were quantitated.
Our method quantitated 5 oxysterols, cholesterol and 25-hydroxy vitamin D3 from 200 μL plasma in 35 minutes. Recoveries were >85% for all analytes and internal standards. The limits of detection were 3-10 ng/mL for oxysterols and 25-hydroxy vitamin D3 and 1 μg/mL for simultaneous detection of cholesterol. Analytical imprecision was <10 %CV for 24(S)-, 25-, 27-, 7α-hydroxycholesterol (HC) and cholesterol and ≤15 % for 7-keto-cholesterol. Multiple Sclerosis and other neurological disorder patients had lower 27-hydroxycholesterol levels compared to controls whereas 7α-hydroxycholesterol was lower specifically in Multiple Sclerosis.
The method is suitable for measuring plasma oxysterols levels in human health and disease. Analysis of human plasma indicates that the oxysterol, bile acid precursors 7α-hydroxycholesterol and 27-hydroxycholesterol are lower in Multiple Sclerosis and may serve as potential biomarkers of disease.
氧化甾醇是与胆固醇和维生素D代谢相关的神经退行性疾病的有前景的生物标志物。目前迫切需要能够灵敏且同时定量多种氧化甾醇、维生素D和胆固醇途径生物标志物的方法。
开发了一种同时测定人血浆中5种主要氧化甾醇、25-羟基维生素D3和胆固醇的方法。通过室温皂化,然后从添加了氘代内标的血浆中进行固相萃取来制备总氧化甾醇。氧化甾醇通过反相高效液相色谱法,使用甲醇/水/0.1%甲酸梯度进行分离。氧化甾醇和25-羟基维生素D3在正离子模式下通过大气压化学电离质谱法进行检测;胆固醇则在204nm处采用串联光电二极管阵列检测。进行了方法验证研究。对来自健康对照受试者、多发性硬化症和其他神经系统疾病患者的220份血浆样本中的氧化甾醇水平进行了定量。
我们的方法在35分钟内从200μL血浆中定量了5种氧化甾醇、胆固醇和25-羟基维生素D3。所有分析物和内标的回收率均>85%。氧化甾醇和25-羟基维生素D3的检测限为3-10ng/mL,胆固醇同时检测的检测限为1μg/mL。24(S)-、25-、27-、7α-羟基胆固醇(HC)和胆固醇的分析精密度<10%CV,7-酮胆固醇的分析精密度≤15%。与对照组相比,多发性硬化症和其他神经系统疾病患者的27-羟基胆固醇水平较低,而7α-羟基胆固醇在多发性硬化症患者中尤其较低。
该方法适用于测量人类健康和疾病状态下的血浆氧化甾醇水平。对人血浆的分析表明,氧化甾醇、胆汁酸前体7α-羟基胆固醇和27-羟基胆固醇在多发性硬化症患者中较低,可能作为疾病的潜在生物标志物。